Beranda › Kondisi Pasca-COVID (Long COVID) › Virginia
Uji klinis Kondisi Pasca-COVID (Long COVID) di Virginia
6 studi untuk Kondisi Pasca-COVID (Long COVID) mencari peserta di lokasi di Virginia.
Teks studi resmi (Bahasa Inggris)
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- Research Site, Charlottesville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05624450A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- Velocity Clinical Research, Suffolk, Suffolk
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06679140A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- Velocity Clinical Research - Hampton ( Site 3744), Hampton
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06667700A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
- GSK Investigational Site, Charlottesville
- GSK Investigational Site, Newport News
Menerima pesertaFase 1
Usia 65 hingga 85 · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT07464314Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- VCU Health System, Richmond
Menerima pesertaFase 3
Semua usia · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT03808922A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
- Richard Bennett - Clinical Research Partners, Richmond
Menerima pesertaFase 4Sukarelawan sehat diterima
6 Months · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06585241Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.